

Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

MV4-11

RRID:CVCL_0064

Type: Cell Line

Proper Citation

RRID:CVCL_0064

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0064

Proper Citation: RRID:CVCL_0064

Description: Cell line MV4-11 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Childhood acute monocytic leukemia

Defining Citation: [PMID:1423625](#), [PMID:2656885](#), [PMID:3496132](#), [PMID:8353274](#), [PMID:8358709](#), [PMID:9195772](#), [PMID:12529668](#), [PMID:14504097](#), [PMID:14671638](#), [PMID:15843827](#), [PMID:16408098](#), [PMID:19608861](#), [PMID:20215515](#), [PMID:20922763](#), [PMID:21552520](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#), [PMID:36982453](#)

Comments: Karyotypic information: 48,XY,t(4;11)(q21;q23),+8,+19 (ATCC=CRL-9591)., Characteristics: CSF2 and IL3 dependent., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MV4-11

Synonyms: MV-4-11, MV-4:11, MV4:11, MV 4;11, MV4;11, MV411, MV(4;11), MV4II

Cross References: BTO:BTO_0006413, CLO:CLO_0007906, EFO:EFO_0002242, CLDB:cl3610, CLDB:cl3611, AddexBio:C0003025/4955, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610,

ATCC:CRL-9591, ATCC:HTB-189, BioGRID_ORCS_Cell_line:138, BioSample:SAMN01821582, BioSample:SAMN01821649, BioSample:SAMN03473104, BioSample:SAMN10988366, cancercellines:CVCL_0064, CCRID:3101HUMSCSP5031, Cell_Model_Passport:SIDM00657, ChEMBL-Cells:ChEMBL3308063, ChEMBL-Targets:ChEMBL613835, CLS:300295, Cosmic:787416, Cosmic:798673, Cosmic:908156, Cosmic:975284, Cosmic:994182, Cosmic:996315, Cosmic:1012104, Cosmic:1037736, Cosmic:1078732, Cosmic:1089516, Cosmic:1127256, Cosmic:1150899, Cosmic:1152712, Cosmic:1181603, Cosmic:1278781, Cosmic:1281340, Cosmic:1308221, Cosmic:1319550, Cosmic:1451846, Cosmic:1476424, Cosmic:1516631, Cosmic:1524837, Cosmic:1623635, Cosmic:1696137, Cosmic:1779133, Cosmic:2131568, Cosmic:2306226, Cosmic:2392908, Cosmic:2393011, Cosmic:2542841, Cosmic:2750867, Cosmic-CLP:908156, DepMap:ACH-000045, DSMZ:ACC-102, DSMZCellDive:ACC-102, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, FANTOM5_SSTAR:10718-10917, GDSC:908156, GEO:GSM236796, GEO:GSM236832, GEO:GSM482560, GEO:GSM887344, GEO:GSM888420, GEO:GSM1374694, GEO:GSM1446746, GEO:GSM1670137, IARC_TP53:21521, IGRhCellID:MV4II, LiGeA:CCLE_055, LINCS_LDP:LCL-1092, Lonza:996, Pharmacodb:MV411_972_2019, PRIDE:PXD030304, Progenetix:CVCL_0064, PubChem_Cell_line:CVCL_0064, TOKU-E:2536, Ubigen:YC-C060, Wikidata:Q54907109

ID: CVCL_0064

Record Creation Time: 20220427T220828+0000

Record Last Update: 20260829T234715+0000

Ratings and Alerts

No rating or validation information has been found for MV4-11.

Warning: Discontinued: ATCC; HTB-189

Karyotypic information: 48,XY,t(4;11)(q21;q23),+8,+19 (ATCC=CRL-9591)., Characteristics: CSF2 and IL3 dependent., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 496 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wu S, et al. (2026) Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine. Molecular oncology, 20(2), 555.

Zhang H, et al. (2026) A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRP?-Independent Mechanism. *Molecular cancer therapeutics*, 25(1), 21.

Lewis AC, et al. (2026) Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia. *Cell*, 189(1), 215.

Eriksson J, et al. (2026) Single-Cell Lineage Tracing Uncovers Resistance Signatures and Sensitizing Strategies to FLT3 Inhibitors in Acute Myeloid Leukemia. *Cancer research*, 86(7), 1724.

Schäfer S, et al. (2026) ACSL4-associated lipid metabolism is a distinct therapeutic vulnerability in KMT2A-rearranged acute myeloid leukemia. *Cell reports*, 45(3), 117010.

Peng M, et al. (2026) MMRN1-EGFR drives sialylglycan-Siglec immune evasion in AML leukemia stem cells. *Cell stem cell*, 33(5), 800.

Zhao S, et al. (2026) RNF25 confers mRNA damage tolerance by curbing activation of the integrated stress response. *Molecular cell*, 86(7), 1275.

Chen TQ, et al. (2026) RBM15B recognizes H3K79me2 to guide selective m6A-modification of mRNA and enhance oncoprotein translation in MLL-r leukemia. *The EMBO journal*, 45(5), 1672.

Saad J, et al. (2026) Predictors of response and rational combinations for the novel MCL-1 inhibitor MIK665 in acute myeloid leukemia. *Molecular oncology*, 20(2), 389.

Chen Y, et al. (2026) DualPG-DTA: A Large Language Model-Powered Graph Neural Network Framework for Enhanced Drug-Target Affinity Prediction and Discovery of Novel CDK9 Inhibitors Exhibiting In Vivo Anti-Leukemia Activity. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(12), e13099.

Zwick M, et al. (2026) FLT3-ITD Induces CMTM6 and Enhances Immune Escape in Acute Myeloid Leukemia. *Cancer research*, 86(2), 367.

Yagüe-Capilla M, et al. (2026) IMPDH inhibition enhances cytarabine efficacy in SAMHD1-expressing leukaemia cells via guanine nucleotide depletion. *Molecular oncology*.

Sun X, et al. (2026) Targeting UGCG sensitizes AML cells to venetoclax through RAB32-mediated endoplasmic reticulum-mitochondria communication. *Cell reports*, 45(3), 117021.

He C, et al. (2026) Biomimetic Copper-Doped Nano-Aluminum Adjuvant Potentiates Therapy in Chemoresistant Acute Myeloid Leukemia. *Advanced healthcare materials*, 15(19), e04039.

Chung J, et al. (2026) Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity. *Science (New York, N.Y.)*, 392(6794), eady5196.

Waclawiczek A, et al. (2026) Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML. *Cell stem cell*, 33(6), 982.

Jin K, et al. (2026) LDLRAD2 drives glycolysis and angiogenesis to promote extramedullary infiltration in acute myeloid leukemia. *iScience*, 29(6), 115987.

Liu Y, et al. (2026) Integrated scFv identification and CAR T cell generation for AML targeting in vivo. *International journal of cancer*, 158(4), 994.

Uible EE, et al. (2026) Scaffolding-dependent CASP1 constrains excessive cell-intrinsic inflammatory signaling in leukemia. *Cell chemical biology*, 33(1), 59.

Pereira-Martins DA, et al. (2026) ?Np73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia. *Cell reports. Medicine*, 102540.